280110-78-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(5-Phenyl-1,3,4-oxadiazol-2-yl)piperidine (minimum 90%) is used as a key intermediate in the synthesis of various drugs due to its potential biological activities. It is particularly valuable for the development of psychiatric, neurological, and cardiovascular medications.
Used in the Synthesis of Psychiatric Medications:
In the pharmaceutical industry, 4-(5-Phenyl-1,3,4-oxadiazol-2-yl)piperidine (minimum 90%) is used as a building block for the creation of psychiatric medications, leveraging its biological properties to address mental health disorders.
Used in the Synthesis of Neurological Medications:
4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)PIPERIDINE(MINIMUM90%) is also utilized in the development of neurological drugs, where its structure and properties can contribute to the treatment of various neurological conditions.
Used in the Synthesis of Cardiovascular Medications:
Furthermore, 4-(5-Phenyl-1,3,4-oxadiazol-2-yl)piperidine (minimum 90%) is employed in the synthesis of cardiovascular drugs, potentially aiding in the management and treatment of heart-related diseases.
The specific applications and properties of 4-(5-Phenyl-1,3,4-oxadiazol-2-yl)piperidine (minimum 90%) are contingent upon the particular research or production process for which it is implemented.

InChI:InChI=1/C13H15N3O/c1-2-4-10(5-3-1)12-15-16-13(17-12)11-6-8-14-9-7-11/h1-5,11,14H,6-9H2

Upstream product

• 613-94-5 benzoic acid hydrazide 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 1031156-54-3 tert-butyl 4-(2-benzoylhydrazinecarbonyl)piperidine-1-carboxylate 
• 280110-70-5 4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 187834-88-4 tert-butyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 1419956-62-9 [4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-piperidin-1-yl]-acetic acid 
• 1419951-13-5 C₂₃H₂₆N₆O₄ 

Relevant academic research and scientific papers

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Discovery of highly potent triazole antifungal agents with piperidine-oxadiazole side chains

Due to increasing incidence and mortality of invasive fungal infections, discovery and development of new generations of antifungal agents represents a challenging task. On the basis of our previously reported triazole-benzyloxypiperidinyl lead compound, a series of novel triazole antifungal agents containing piperidine-oxadiazole side chains were rationally designed and synthesized. Most of the target compounds showed excellent inhibitory activity against clinically important fungal pathogens. In particular, compounds 6g (MIC = 0.031 μg mL-1) and 11b (MIC = 0.016 μg mL-1) were highly active against Candida albicans including fluconazole-resistant strains. Moreover, they showed inhibitory activity against hyphal formation with low toxicity, which were promising leads for further development. This journal is

NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS

The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.